J
Jing Liu
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 105
Citations - 2988
Jing Liu is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Chemistry & Medicine. The author has an hindex of 23, co-authored 71 publications receiving 1827 citations. Previous affiliations of Jing Liu include University of North Carolina at Chapel Hill & Brigham Young University.
Papers
More filters
Journal ArticleDOI
In silico design of novel probes for the atypical opioid receptor MRGPRX2
Katherine Lansu,Joel Karpiak,Jing Liu,Xi Ping Huang,John D. McCorvy,Wesley K. Kroeze,Tao Che,Hiroshi Nagase,Frank I. Carroll,Jian Jin,Brian K. Shoichet,Bryan L. Roth +11 more
TL;DR: MRGPRX2 is a unique atypical opioid-like receptor important for modulating mast cell degranulation, which can now be specifically modulated with ZINC-3573, which represents a potent MRG PRX2-selective agonist, showing little activity against 315 other GPCRs and 97 representative kinases.
Journal ArticleDOI
A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases
Mohammad S. Eram,Yudao Shen,Magdalena M. Szewczyk,Hong Wu,Guillermo Senisterra,Fengling Li,Kyle V. Butler,H. Uemit Kaniskan,Brandon A. Speed,Carlo C. dela Seña,Aiping Dong,Hong Zeng,Matthieu Schapira,Matthieu Schapira,Peter Brown,Cheryl H. Arrowsmith,Cheryl H. Arrowsmith,Dalia Barsyte-Lovejoy,Jing Liu,Masoud Vedadi,Masoud Vedadi,Jian Jin +21 more
TL;DR: The discovery of a potent, selective, and cell-active inhibitor of human type I PRMTs, MS023, and characterization of this inhibitor in a battery of biochemical, biophysical, and cellular assays are reported.
Journal ArticleDOI
Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
TL;DR: This study developed MS4748 and MS4740, very close analogs of 5 and 6 respectively, which are incapable to degrade the ALK fusion proteins, as negative controls, which paved the way for developing the next generation of ALK PROTACs.
Journal ArticleDOI
Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys.
Yuji Nagai,Naohisa Miyakawa,Hiroyuki Takuwa,Yukiko Hori,Kei Oyama,Bin Ji,Manami Takahashi,Xi Ping Huang,Samuel T. Slocum,Jeffrey F. DiBerto,Yan Xiong,Takuya Urushihata,Toshiyuki Hirabayashi,Atsushi Fujimoto,Koki Mimura,Justin G. English,Jing Liu,Ken-ichi Inoue,Ken-ichi Inoue,Katsushi Kumata,Chie Seki,Maiko Ono,Masafumi Shimojo,Ming-Rong Zhang,Yutaka Tomita,Jin Nakahara,Tetsuya Suhara,Masahiko Takada,Makoto Higuchi,Jian Jin,Bryan L. Roth,Takafumi Minamimoto +31 more
TL;DR: DCZ represents a potent, selective, metabolically stable and fast-acting DREADD agonist with utility in both mice and nonhuman primates for a variety of applications.
Journal ArticleDOI
MERTK receptor tyrosine kinase is a therapeutic target in melanoma
Jennifer Schlegel,Maria J. Sambade,Susan Sather,Stergios J. Moschos,Aik Choon Tan,Amanda Winges,Deborah DeRyckere,Craig C. Carson,Dimitri G. Trembath,John J. Tentler,S. Gail Eckhardt,Pei Fen Kuan,Ronald L. Hamilton,Lyn M. Duncan,C. Ryan Miller,Nana Nikolaishvili-Feinberg,Bentley R. Midkiff,Jing Liu,Weihe Zhang,Chao Yang,Xiaodong Wang,Stephen V. Frye,H. Shelton Earp,Janiel M. Shields,Douglas K. Graham +24 more
TL;DR: It is demonstrated that MERTK expression correlates with disease progression and is established as a therapeutic target in melanoma and provides a rationale for the continued development of MertK-targeted therapies.